Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple ...

Medtronic has announced plans to double the footprint of its London office, focused on developing artificial intelligence and ...

Rome’s pipeline is built on twin franchise, one composed of reverse transcriptase inhibitors and another pursuing tumor ...

Glooko is looking to expand its diabetes treatment platforms to the inpatient setting, with a plan to acquire Monarch Medical ...

The New York Stock Exchange helped ring in this year’s Fierce 15 by honoring the winners on the trading floor Monday morning.

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate ...

Tuesday morning, Seres confirmed that one of these actions would involve reducing its workforce by 25%. Employees who are “most critical” for the preparations for the phase 2 study will be spared, ...

But, in the Gemini trials, tolebrutinib failed on the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when ...

When Roche unveiled its long-awaited obesity strategy yesterday, it included a b | Roche’s head of metabolic product development said the company is firing “on full cylinders” to get a phase 3 trial ...

Roche has reported a phase 3 win for its oral selective estrogen receptor degrader (SERD), bouncing back from an earlier ...

PacBio aims to dive deeper into the family planning market with an updated carrier screening kit designed to take multiple ...

Angelini Pharma has worked out a $550 million-plus biobucks deal to get its hands on a Korean biotech’s preclinical neuro ...